Literature DB >> 28112380

miR520c blocks EMT progression of human breast cancer cells by repressing STAT3.

Nian Wang1, Lan Wei1, Yunxiu Huang1, Yang Wu1, Min Su1, Xueli Pang1, Nian Wang1, Feihu Ji1, Changli Zhong1, Tingmei Chen1, Bing Li1.   

Abstract

Breast cancer is one of the most malignant diseases world-wide and it ranks the first among female cancers. Masses of intrinsic and extrinsic factors, especially the inflammatory factors can lead to breast cancer. Aberrant activation and accumulation of key molecules can lead to inflammation associated carcinogenesis. The signal transducers and activators of transcription 3 (STAT3) is one of them. Therefore, to evaluate the novel molecular mechanisms, STAT3 has become our focus for breast cancer targeted therapy. At present, many tumor suppressing microRNAs have been validated, and are the highlights in research on microRNAs. Thus, we predicted microRNAs which could putatively regulate STAT3 through databases and selected six to screen with Dual-luciferase assay. The result hinted that miR520c could bind with STAT3 3'UTR. We mutated the seed sequence of miR520c on STAT3 3'UTR, which illustrated a reverse effect compared with wild-type of STAT3 3'UTR. Subsequently, STAT3, p-STAT3 and miR520c were assessed in three different grades of breast cancer cells, with the degree of malignancy, we found an escalating trend of STAT3 and p-STAT3, on the contrary, a downward trend of miR520c. We observed STAT3 was deactivated by miR520c. Epithelial to mesenchymal transition (EMT) is a fatal transfer of cancer progression. To find out whether the downregulation of STAT3 can repress breast cancer motility and invasion ability, we detected EMT markers. The result implied a suppression effect on EMT. We overexpressed STAT3 to conduct rescue experiments, the result showed a recovery of STAT3 and EMT characteristics. Cell motility and invasion property were regained as well. In the study, we elucidated miR520c could inhibit breast cancer EMT by targeting STAT3. It can enrich the mechanism of breast cancer and may lay the foundation for breast cancer targeted treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28112380     DOI: 10.3892/or.2017.5393

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  TLR5: A prognostic and monitoring indicator for triple-negative breast cancer.

Authors:  Dai Shi; Shanshan Zhao; Wen Jiang; Chao Zhang; Ting Liang; Guihua Hou
Journal:  Cell Death Dis       Date:  2019-12-18       Impact factor: 8.469

Review 2.  Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective.

Authors:  Ajay Kumar Pal; Prateek Sharma; Alishan Zia; Deepali Siwan; Dipali Nandave; Mukesh Nandave; Rupesh K Gautam
Journal:  Pathophysiology       Date:  2022-05-27

Review 3.  The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas.

Authors:  Monica Fedele; Laura Cerchia; Gennaro Chiappetta
Journal:  Cancers (Basel)       Date:  2017-09-30       Impact factor: 6.639

4.  STAT3 polymorphisms in North Africa and its implication in breast cancer.

Authors:  Wafa Ziadi; Sami Boussetta; Sarra Elkamel; Andrew J Pakstis; Kenneth K Kidd; Imen Medimegh; Amel Ben Ammar Elgaaied; Lotfi Cherni
Journal:  Mol Genet Genomic Med       Date:  2021-07-12       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.